Skip to content
Search

Latest Stories

Submit Guest Post

NHS to launch trial for world’s first norovirus vaccine

Norovirus infects around four million people annually in the UK, leading to 12,000 hospitalisations and about 80 deaths.

The vaccine, based on mRNA technology, aims to prevent the highly contagious virus that causes vomiting and diarrhoea. (Representational image: iStock)
The vaccine, based on mRNA technology, aims to prevent the highly contagious virus that causes vomiting and diarrhoea. (Representational image: iStock)

THE WORLD's first vaccine for norovirus, developed by US company Moderna, will be trialled on NHS patients this winter.

The vaccine, based on mRNA technology, aims to prevent the highly contagious virus that causes vomiting and diarrhoea.


The Times reported that the trial will involve 2,500 participants, mostly elderly patients.

Norovirus infects around four million people annually in the UK, leading to 12,000 hospitalisations and about 80 deaths. There is currently no vaccine for the virus.

Moderna’s new vaccine, mRNA-1403, has shown a strong immune response to multiple strains of norovirus in earlier trials. The vaccine’s development is part of a ten-year partnership between the UK government and Moderna, which aims to position the UK as a leader in life sciences.

The trial will recruit participants from 27 NHS hospitals and clinics across England, Scotland, and Wales.

Mobile clinics may visit care homes and community sites to include elderly individuals. Half of the participants will receive the vaccine, while the other half will receive a placebo.

The trial will track the participants for around 25 months to assess the vaccine’s effectiveness, with researchers aiming for a 65 per cent or higher efficacy rate. If successful, the vaccine could be available on the NHS by 2026, The Times reported.

Health Secretary Wes Streeting highlighted the burden norovirus places on the NHS, costing taxpayers around £100 million annually. He said the trial could shift the focus of the health system from treating illness to prevention.

Experts are hopeful that the vaccine will eventually be used seasonally, similar to the flu jab, or potentially offer lifelong immunity, The Times reported.

The trial is led by Dr Patrick Moore, a GP in Dorset, with participation from other countries including the US, Canada, and Japan.

Researchers hope the vaccine will reduce the impact of norovirus on healthcare systems and workplaces.

Add EasternEye As Your Trusted Source
preferred source on google news

More For You

James Cleverly

Sir James Cleverly speaks after being selected as the Conservative Party's candidate for Mayor of London on Thursday (19)

REUTERS

James Cleverly selected as Conservative candidate to challenge Sadiq Khan in 2028

  • Cleverly secured 86 per cent of the first-round vote in the Conservative selection.
  • He will not seek re-election as an MP, saying he is fully committed to the mayoral campaign.
  • Sadiq Khan has not yet confirmed whether he will seek a fourth term in 2028.

Former home secretary Sir James Cleverly has been selected as the Conservative Party's candidate for the 2028 London mayoral election, setting up a potential contest with Labour incumbent Sir Sadiq Khan.

Cleverly received 86 per cent of the first-round vote among London Conservative members, securing the nomination ahead of the next election, scheduled for May 2028.

Keep ReadingShow less